BPC-157 for the gut: what the studies show

Reviewed 24 sourcesPublished by PepVault

BPC-157 for the gut: rat studies on ulcers, NSAID damage, colitis and fistulas, the one ulcerative colitis trial in people, and why it survives the stomach.

Silver-haired man in a navy tee jogs along the water’s edge on a palm-fringed beach
Last reviewed
Sources
24
Questions
10
Compounds
3

The short answer

In rats, BPC-157 has healed stomach ulcers, NSAID damage, colitis and bowel fistulas, given by injection or in drinking water, mostly in studies by the Zagreb group that discovered it. In people, the only gut trial is a 2005 abstract: 53 patients with ulcerative colitis took BPC-157 enemas or placebo for two weeks, and the difference was too small to rule out chance.

  • Rats: protection from NSAID ulcers, healed colitis and closed fistulas, by injection or in drinking water.
  • People: one two-week enema trial in 53 people with ulcerative colitis, reported only as a 2005 abstract; it could not separate BPC-157 from placebo.
  • It survives human gastric juice, which is why it works by mouth in rats; whether it reaches the blood from the gut is unknown.
  • No study has measured leaky gut on BPC-157, and nearly three in four of its PubMed records carry one researcher's name.

Every number checked at its primary source · · 24 sources · How we research

Evidence: Animal studies, almost all in rats and mostly from one group, plus one small placebo-controlled enema trial in ulcerative colitis known only from a 2005 meeting abstract; no published full trial in any gut condition as of November 2026.

Silver-haired man in a navy tee jogs along the water’s edge on a palm-fringed beach

Does BPC-157 work for the gut?

In rats, along nearly the whole length of the gut. BPC-157 is a chain of 15 amino acids cut from a protein its discoverers found in human gastric juice, and its developers first took it forward as a gut drug1216. Here is the gut from top to bottom, with what was tested at each stop.

Part of the gutWhat the rats hadHow BPC-157 was givenWhat happened
EsophagusReflux after the stomach was removedDrinking waterLess inflamed lining over 28 days than with ranitidine or sucralfate14
StomachUlcers from aspirin, indomethacin or diclofenacInjection into the bellyLesions more than 75% smaller315
StomachUlcers in three models, including acetic acidMuscle injection or stomach tubeUlcer formation cut by 46% to 66%5
Small bowelMost of the small bowel removedDrinking water or belly injectionSteady weight gain above the pre-surgery level, through 4 weeks13
ColonColitis from chemicals or a cut blood supplyBelly injection, drinking water or a bath on the colonColitis healed; untreated rats did not heal78
Bowel to skin, bladder or vaginaA surgically made fistulaDrinking water or belly injectionFistulas closed; untreated ones kept leaking9101112

Species note: every result in the table is from rats, given amounts per kilogram of body weight. None of it is a dose for a person, and a result in a rat is not proof of one in people.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault records each compound's route. An oral dose logs with one tap and an injection asks for its site, so your log shows what went in, and how, on each day.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Does BPC-157 protect the stomach from NSAIDs?

In rats, strongly. NSAIDs are painkillers such as ibuprofen, aspirin and diclofenac, and at high doses they wear holes in the stomach and small bowel. In the developers' 1997 study, rats given BPC-157 with one of three NSAIDs had stomach lesions more than 75% smaller, by FDA's reading315. In 2011, rats given diclofenac for three days got severe stomach, bowel and liver damage, and BPC-157 prevented it whether injected or added to their drinking water4.

A team outside Zagreb, in Xi'an, China, tested it in three rat ulcer models in 2004. At the higher doses it cut ulcer formation by 45.7% to 65.6%, and by muscle injection it beat famotidine, a standard acid-reducing drug, in all three models. Through a stomach tube it worked too, but less well5.

FDA's 2026 review notes two limits: most NSAID studies gave BPC-157 before or with the painkiller, so healing of damage already set in was not tested there, and doses a thousand times apart worked equally well, so no dose-response was shown15.

Does BPC-157 help colitis or IBD?

In rat colitis, yes, and one of the first tests came from a US drug company. In 1995 a Parke-Davis team in Ann Arbor, Michigan, gave rats colitis with TNBS, a chemical that kills patches of the colon lining. BPC-157 injected into the belly an hour before shrank the damage, and the more they gave, the smaller it was. Put straight into the colon, at the one dose they tried, it did not help6.

The Zagreb group has since healed cysteamine colitis, which untreated rats could not heal, with BPC-157 by injection or in drinking water7. When a stretch of colon had its blood supply tied off, BPC-157 bathed onto it brought vessels back into view within 15 minutes8.

IBD, inflammatory bowel disease, covers ulcerative colitis and Crohn's disease. For Crohn's, and for celiac disease, FDA found no human study at all in 202615.

Has BPC-157 been tested for ulcerative colitis in people?

Once, and the record is thinner than its reputation. The Croatian drug company Pliva developed it for inflammatory bowel disease under the codes PL-10, PLD-116 and PL 1473617. Its trials are often dated to the 1990s; the primary records show two enema trials, reported only as meeting abstracts in 2002, 2003 and 2005, and neither has appeared as a full paper in PubMed20. FDA's 2026 review lays both out15.

TrialWhoWhat they gotWhat it found
Phase 1, abstracts 2002 and 20031532 healthy men; 24 got BPC-157, 8 placeboAn enema of 0.25 to 2 mg per kg once, then, after a week's break, daily for 7 daysNo adverse events put down to it; headache and flatulence as often as on placebo
Phase 2, abstract 20051553 people with mild to moderate ulcerative colitis; 46 finishedAn 80 mg enema or placebo, once a day for 2 weeksDisease score down 3.2 points on BPC-157 and 1.6 on placebo

The 1.6-point gap had a 95% confidence interval from -4.84 to 1.62, which crosses zero: the trial could not tell BPC-157 from placebo. Three people on BPC-157 and two on placebo were withdrawn for adverse events, mainly worsening colitis. FDA's July 2026 verdict: too little data to show it works or is safe for ulcerative colitis, and two weeks says little about a disease treated for years15.

In both trials BPC-157 was not found in measurable amounts in the blood after an enema, and FDA concluded it does not appear to be absorbed that way15. In people, the one gut route tested seems to stay in the gut.

The enema amounts in the table are what the trials used. They describe the research, not a protocol to copy.

Does BPC-157 heal fistulas and gut surgery?

In rats, often fully. A fistula is a tunnel that forms between the bowel and another organ or the skin, and some never close. In rats with one from the colon to the skin, the openings were about 40% smaller from day 3 on BPC-157 and had closed by day 28, while untreated ones shrank by less than 10% on the skin side915. Sulfasalazine, a standard colitis drug, helped only moderately, and a steroid made healing worse9.

With fistulas from the duodenum, the first stretch of small bowel, to the colon, every treated rat closed both openings and kept its weight10. It also closed fistulas from the colon to the bladder11 and from the rectum to the vagina12. Surgical joins in the bowel held more pressure before leaking17, and rats missing most of their small bowel gained weight instead of wasting13. The study page pepvault.app/research/bpc-157-vukusic-2024 walks through the duodenal one.

Is there evidence for BPC-157 and leaky gut?

Not directly. "Leaky gut" means a gut lining that lets more through the gaps between its cells than it should. The case for BPC-157 rests on a 2020 review by Korean researchers and the Zagreb group, which argues from the NSAID-damage studies that it should protect that lining18. In PubMed's records as of November 20, 2026, we found no study that measured gut permeability in an animal or a person given it20. The rat studies scored bigger, visible damage, so the leaky-gut claim runs ahead of the data.

Why does BPC-157 work by mouth when most peptides don't?

Because stomach juice does not break it down. Most peptides are cut apart by acid and pepsin, the stomach's protein-cutting enzyme, at a pH of 1 to 219. BPC-157 comes from a protein in that juice, and in a 1995 lab test it held up in human gastric juice15. That is why so many gut studies simply put it in the rats' drinking water7913.

Surviving the stomach is only the first step. Whether it then crosses the gut wall into the blood is unknown in any species; even the standard lab test of a drug passing through a layer of human gut cells has not been published for it19. For gut problems that may matter less, since a swallowed or rectal dose meets the gut lining directly. Our guide to BPC-157 by mouth, nose and injection compares every route.

PepVault records each compound's route. An oral dose logs with one tap and an injection asks for its site, so your log shows what went in, and how, on each day. Log it in PepVault

Who did the gut research on BPC-157?

Mostly one group. Of 242 PubMed records on BPC-157, 176 (73%) carry the name of Predrag Sikiric, whose University of Zagreb team discovered it20. The independent pieces, Parke-Davis on colitis6 and Xi'an on ulcers5, point the same way but are few. FDA adds that the molecule it binds to is unknown15. As of November 2026, no trial in a gut condition is registered on ClinicalTrials.gov21.

What do people who take BPC-157 for the gut report?

Commonly reported: a calmer gut. In our count of 69 people's own posts about BPC-157 (checked November 19, 2026), 8 described one, tied for second after faster healing of an injury.

These are user reports, not trial results, and gut symptoms swing on their own. To see a real change, track it the same way every day:

  1. Pick the one symptom you care about most, such as bloating or reflux.
  2. Rate it from 1 to 5 at the same time every day for a week before anything changes.
  3. Change one thing at a time, so a shift has one likely cause.
  4. Keep rating the same symptom on the same scale, and note meals that set it off.
  5. Compare whole weeks before and after, not single days.

In PepVault's side-effects log you can name a symptom such as bloating, rate it from 1 to 5 against the compound it belongs to, and read your entries back by date. Log it in PepVault

When to get help Blood in the stool, diarrhea that won't settle, or weight loss you can't explain are reasons to see a doctor first: they can be signs of inflammatory bowel disease, which has approved treatments15.

Is BPC-157 approved for gut conditions?

No. As of November 2026 it is not an FDA-approved drug for any use15. In July 2026 FDA staff reviewed it for ulcerative colitis, for the list of substances US pharmacies may compound from, and found a lack of evidence that it works for that disease15. FDA's advisory committee recommended listing it anyway, and on October 30, 2026, HHS said it would not act against licensed US pharmacies and doctors compounding it, under set conditions, while FDA builds that list2324. WADA's 2026 list bans it for tested athletes at all times22; pepvault.app/peptides/bpc-157/legal-status tracks the changes.

Track it in the app

Sources

  1. Sikirić P et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993. PubMed 8298609
  2. Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011. PubMed 21548867
  3. Sikiric P et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol Paris. 1997. PubMed 9403784
  4. Ilic S et al. Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci. 2011. PubMed 21295044
  5. Xue XC et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004. PubMed 15052688
  6. Veljaca M et al. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther. 1995. PubMed 7815358
  7. Klicek R et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013. PubMed 24304574
  8. Duzel A et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World J Gastroenterol. 2017. PubMed 29358856
  9. Klicek R et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats. J Pharmacol Sci. 2008. PubMed 18818478
  10. Vukusic D et al. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint. J Physiol Pharmacol. 2024. PubMed 38583442
  11. Grgic T et al. Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula. Eur J Pharmacol. 2016. PubMed 26875638
  12. Baric M et al. Stable gastric pentadecapeptide BPC 157 heals rectovaginal fistula in rats. Life Sci. 2016. PubMed 26872976
  13. Sever M et al. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci. 2009. PubMed 19093208
  14. Sikiric P et al. Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats. J Physiol Paris. 1999. PubMed 10672991
  15. U.S. Food and Drug Administration. Briefing document: BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. fda.gov
  16. Sikiric P et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012. PubMed 22300085
  17. Vuksic T et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today. 2007. PubMed 17713731
  18. Park JM, Lee HJ, Sikiric P, Hahm KB. BPC 157 rescued NSAID-cytotoxicity via stabilizing intestinal permeability and enhancing cytoprotection. Curr Pharm Des. 2020. PubMed 32445447
  19. Mateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026. PubMed 42198317
  20. PubMed search, November 20, 2026: (BPC 157 OR BPC-157 OR BPC157 OR PL 14736) gives 242 records; adding AND Sikiric P[au] gives 176. pubmed.ncbi.nlm.nih.gov
  21. ClinicalTrials.gov search for BPC-157, BPC157, PL14736 and Bepecin, November 20, 2026. clinicaltrials.gov
  22. World Anti-Doping Agency. The 2026 Prohibited List, S0 Non-approved substances (in effect from January 1, 2026). wada-ama.org
  23. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, October 30, 2026 (FR Doc. 2026-22192). federalregister.gov
  24. Akin Gump. HHS announces interim enforcement discretion policy for compounding six peptides (November 10, 2026). akingump.com

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo